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ABSTRACT

The present invention relates to methods of treatment of a
disease or pathology of the central nervous system, an eating
disorder, or substance use disorder, drug dependence/abuse
and withdrawal therefrom comprising administering at least
one N-phenylalkyl amphetamine derivative and pharmaceutical compositions comprising at least one N-phenylalkyl
amphetamine derivative to an individual in need thereof.

4 Claims, No Drawings
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VESICULAR MONOAMINE
TRANSPORTER-2 LIGANDS AND THEIR
USE IN THE TREATMENT OF
PSYCHOSTIMULANT ABUSE

carboxylate;
isopropylcarboxylate;
carboxaldehyde;
acetoxy; propionyloxy; isopropionyloxy; cyano; aminomethyl; N-methylaminomethyl; N,N-dimethylaminomethyl;
carboxamide; N-methylcarboxamide; N,N-dimethylcarboxamide; acetyl; propionyl; formyl; benzoyl sulfate; phenyl;
methylsulfate; hydroxyl; methoxy; ethoxy; propoxy; isopropoxy; thiol; methylthio; ethylthio; propiothiol; fluoro;
chloro; bromo; iodo; trifluoromethyl; vinyl; ally!; propargyl;
nitro; carbamoyl; ureido; azido; isocyanate; thioisocyanate;
hydroxylamino; nitroso; a saturated or unsaturated hydrocarbon ring; a nitrogen containing heterocyclic moiety; an
oxygen containing heterocyclic moiety; a sulfur containing
heterocyclic moiety; a selenium containing heterocyclic
moiety; a mixed heterocyclic moiety containing at least two
atoms selected from the group consisting of nitrogen, oxygen and sulfur; and ortho, meta or para-substituted benzene;
R3 is a methyl, ethyl, propyl, isopropyl, hydroxymethyl,
2-hydroxyethyl,
1-hyhydroxyethyl,
methoxymethyl,
2-methoxyethyl, 1-methoxyethyl, aminomethyl, 2-aminoethyl, 1-aminoethyl, N-methylaminomethyl, 2-N-methylaminoethyl, 1-N-methylaminoethyl, N,N-dimethylaminomethyl,
2-N,N-dimethylaminoethyl,
or
1-N,Ndimethylaminoethyl group; and
R4 is a hydrogen atom, a methyl, ethyl, propyl, or isopropyl group.
The compound of formula (I) may form pharmaceutically
acceptable salts with a variety of acids.

5

FIELD OF THE INVENTION
The present invention relates to methods treatment of a
disease or pathology of the central nervous system, an eating
disorder, or substance use disorder, drug dependence/abuse
and withdrawal therefrom comprising administering N-phenylalkyl amphetamine derivatives and pharmaceutical compositions containing these compounds to an individual in
need thereof.
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BACKGROUND OF THE INVENTION
The action of many therapeutic neuropharmacological
agents involve the modulation of dopamine (DA), norepinephrine (NE) and serotonin (5-HT) release, uptake and
storage within their respective terminals in the central nervous system (CNS). Most neurotransmitters are stored in
synaptic vesicles, which are prominent features of nerve
terminals. Sequestration into vesicles appears to be responsible for maintaining a ready supply of neurotransmitter
molecules available for neuronal exocytotic release into the
synaptic cleft. Vesicles also serve the role of protecting the
neurotransmitter molecules from metabolic breakdown. One
transport site on the vesicle membrane is the vesicular
monoamine transporter-2 (VMAT2), whose role is to transport transmitters from the cytosol into the synaptic vesicle.
Once the neurotransmitter is released from the terminal into
the synaptic space, it interacts with postsynaptic receptors
and subsequently is taken back up into the terminal via the
plasma membrane transporter (e.g., DAT and/or the serotonin transporter [SERT]). Thus, transporter proteins modify
the concentration of neurotransmitters in the cytosolic and
vesicular storage pools, and thereby have the ability to alter
subsequent neurotransmission.
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DETAILED DESCRIPTION OF THE
INVENTION
The present invention provides a compound of formula
(I):

35
(I)

40

SUMMARY OF THE INVENTION
The present invention provides a compound of formula
(I):
45
(I)

50

wherein
m is an integer in the range from 1 to 3;
n is zero or an integer in the range from 1 to 5;
R 1 is an aryl group which may be substituted by one or
more substituents;
R2 is an aryl group which may be substituted by one or
more substituents;
wherein substituents on R 1 and R 2 are independently
selected from the group consisting of methyl; deuteromethyl
(CD 3 ); tritiomethyl (CT3 ); ethyl; propyl; isopropyl; C4 -C 7
straight chain or branched alkyl; C 3 -C 6 cycloalkyl; C4 -C 7
alkenyl (including cis and trans geometrical forms); benzyl;
phenylethyl; amino; N-methylamino; N,N-dimethylamino;
carboxylate; methylcarboxylate; ethylcarboxylate; propyl-
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wherein
m is an integer in the range from 1 to 3;
n is zero or an integer from 1 to 5;
R 1 and R 2 are each independently an aryl group,
wherein R 1 and R 2 are each independently unsubstituted
or substituted by one or more substituents selected from the
group consisting of methyl; deuteromethyl (CD 3 ); tritiomethyl (CT 3 ); ethyl; propyl; isopropyl; C4 -C 7 straight chain or
branched alkyl; C 3 -C 6 cycloalkyl; C4 -C 7 alkenyl; benzyl;
phenylethyl; amino; N-methylamino; N,N-dimethylamino;
carboxylate; methylcarboxylate; ethylcarboxylate; propylcarboxylate;
isopropylcarboxylate;
carboxaldehyde;
acetoxy; propionyloxy; isopropionyloxy; cyano; aminomethyl; N-methylaminomethyl; N,N-dimethylaminomethyl;
carboxamide; N-methylcarboxamide; N,N-dimethylcarboxamide; acetyl; propionyl; formyl; benzoyl sulfate; phenyl;
methylsulfate; hydroxyl; methoxy; ethoxy; propoxy; isopropoxy; thiol; methylthio; ethylthio; propiothiol; fluoro;
chloro; bromo; iodo; trifluoromethyl; vinyl; ally!; propargyl;
nitro; carbamoyl; ureido; azido; isocyanate; thioisocyanate;
hydroxylamino; nitroso; a saturated or unsaturated hydrocarbon ring; a nitrogen-containing heterocyclic moiety; an
oxygen-containing heterocyclic moiety; a sulfur-containing
heterocyclic moiety; a selenium-containing heterocyclic
moiety; a mixed heterocyclic moiety containing at least two
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atoms selected from the group consisting of nitrogen, oxygen and sulfur; and ortho, meta or para-substituted benzene;
R3 is methyl, ethyl, propyl, isopropyl, hydroxymethyl,
2-hydroxyethyl,
1-hyhydroxyethyl,
methoxymethyl,
2-methoxyethyl, 1-methoxyethyl, aminomethyl, 2-aminoethyl, 1-aminoethyl, N-methylaminomethyl, 2-N-methylaminoethy1, 1-N-methylaminoethyl, N,N-dimethy laminomethy l,
2-N,N-dimethylaminoethyl,
or
1-N,Ndimethylaminoethyl group; and
R4 is a hydrogen atom or a methyl, ethyl, propyl, or
isopropyl group; or
an enantiomer; racemate; or pharmaceutically acceptable
salt thereof.
A further embodiment of the invention is a compound of
formula (I), wherein: m is 1 or 2; and n is an integer from
1 to 5; or an enantiomer; racemate; or pharmaceutically
acceptable salt thereof.
An further embodiment of the invention is a compound of
formula (I), wherein: m is 1 or 2; and n is an integer from
1 to 5; R3 is methyl, ethyl, propyl, or isopropyl; and R4 is a
hydrogen atom or a methyl, ethyl, propyl, or isopropyl
group; or an enantiomer; racemate; or pharmaceutically
acceptable salt thereof.
A further embodiment of the invention is a compound of
formula (I), wherein: m is 1 or 2; and n is an integer from
1 to 5; wherein R3 is methyl; and R4 is a hydrogen atom or
a methyl group; or an enantiomer; racemate; or pharmaceutically acceptable salt thereof.
Another embodiment of the invention is a compound of
formula (I), wherein m is 1; n is 1; R 1 and R 2 are each
independently a phenyl group, wherein R 1 and R 2 are each
independently unsubstituted or substituted by one or more
substituents selected from the group consisting of benzyl;
amino; hydroxyl; methoxy; fluoro; bromo; and nitroso; R3 is
methyl; and R4 is a hydrogen atom or a methyl group; or an
enantiomer; racemate; or pharmaceutically acceptable salt
thereof.
Another embodiment of the invention is a compound of
formula (I), wherein m is 1; n is 2; R 1 and R 2 are each
independently a phenyl group, wherein R 1 and R 2 are each
independently unsubstituted or substituted by one or more
substituents selected from the group consisting of benzyl;
amino; hydroxyl; methoxy; fluoro; bromo; and nitroso; R3 is
methyl; and R4 is a hydrogen atom or a methyl group; or an
enantiomer; racemate; or pharmaceutically acceptable salt
thereof.
Another embodiment of the invention is a compound of
formula (I), wherein m is 2; n is 1; R 1 and R 2 are each
independently a phenyl group, wherein R 1 and R 2 are each
independently unsubstituted or substituted by one or more
substituents selected from the group consisting of methoxy
and bromo; R3 is methyl; and R4 is a hydrogen atom; or an
enantiomer; racemate; or pharmaceutically acceptable salt
thereof.
Yet another embodiment of the invention is a compound
of formula (I), wherein m is 2; n is 2; R 1 and R 2 are each
independently a phenyl group, wherein R 1 and R 2 are each
independently unsubstituted or substituted by one or more
methoxy groups; R3 is methyl; and R4 is a hydrogen atom or
a methyl group; or an enantiomer; racemate; or pharmaceutically acceptable salt thereof.
Yet another embodiment of the invention is a compound
of formula (I), wherein m is 1; n is an integer from 3 to 5;
R 1 and R 2 are each independently a phenyl group, wherein
R 1 and R 2 are each independently unsubstituted or substituted by one or more substituents selected from the group
consisting of methoxy and bromo; R3 is methyl; and R4 is a

hydrogen atom; or an enantiomer; racemate; or pharmaceutically acceptable salt thereof.
Yet another embodiment of the invention is a compound
of formula (I), wherein mis 1; n is 2; R 1 is an unsubstituted
phenyl group; R 2 is a phenyl group substituted with a
methoxy group; R3 is methyl; and R4 is a hydrogen atom; or
an enantiomer; racemate; or pharmaceutically acceptable
salt thereof.
Compounds of formula (I) include the following compounds:
1. m=l, n=l, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
2. m=l, n=l, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =CH 3
3. m=l, n=l, R 1 =4-BrPh, R 2 =Ph, R 3 =Me, R4 =H
4. m=l, n=2, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
5. R-, m=l, n=2, R 1 =Ph, R 2 =Ph, R3 =Me, R4 =H
6. S-, m=l, n=2, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
7. m=l, n=2, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =CH 3
8. m=l, n=2, R 1 =Ph, R 2 =4-MeOPh, R 3 =Me, R4 =H
9. R-, m=l, n=2, R 1 =Ph, R 2 =4-MeOPh, R 3 =Me, R4 =H
10. S-, m=l, n=2, R 1 =Ph, R 2 =4-MeOPh, R 3 =Me, R4 =H
11. m=l, n=2, R 1 =4-BrPh, R 2 =Ph, R 3 =Me, R4 =H
12. R-, m=l, n=2, R 1 =4-BrPh, R 2 =Ph, R 3 =Me, R4 =H
13. S-, m=l, n=2, R 1 =4-BrPh, R 2 =Ph, R 3 =Me, R4 =H
14. m=l, n=3, R 1 =4-BrPh, R 2 =Ph, R 3 =Me, R4 =H
15. m=l, n=3, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
16. m=l, n=2, R 1 =4-BrPh, R 2 =4-MeOPh, R 3 =Me, R4 =H
17. m=l, n=4, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
18. m=l, n=5, R 1 =Ph, R 2 =Ph, R 2 =Me, R4 =H
19. m=l n=l, R 1 =Ph, R 2 =PhO, R 3 =Me, R4 =H
20. m=l, n=l, R 1 =4-BrPh, R 2 =PhO, R 3 =Me, R4 =H
21. m=l, n=l, R 1 =Ph, R 2 =4-OHPh, R 3 =Me, R4 =H
22. m=l, n=l, R 1 =Ph, R 2 =3,4-diBnOPh, R 3 =Me, R4 =H
23. m=l, n=l, R 1 =Ph, R 2 =3,4-diOHPh, R 3 =Me, R4 =H
24. m=l, n=l, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
25. m=l, n=l, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =CH 3
26. m=l, n=2, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
27. R-, m=l, n=2, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
28. S-, m=l, n=2, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
29. m=l, n=2, R 1 =4-MeOPh, R 2 =4-MeOPh, R 3 =Me, R4 =H
30. m=l, n=2, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =CH 3
31. m=2, n=l, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
32. m=2, n=2, R 1 =4-MeOPh, R 2 =Ph, R 3 =Me, R4 =H
33. m=2, n=l, R 1 =4-MeOPh, R 2 =4-MeOPh, R 3 =Me, R4 =H
34. m=2, n=l, R 1 =4-MeOPh, R 2 =4-BrPh, R 3 =Me, R4 =H
35. m=l, n=l, R 1 =4-OHPh, R 2 =Ph, R 3 =Me, R4 =H
36. m=l, n=2, R 1 =4-OHPh, R 2 =4-MeOPh, R 3 =Me, R4 =H
37. m=l, n=2, R 1 =4-OHPh, R 2 =Ph, R 3 =Me, R4 =H
38. m=l, n=l, R 1 =4-FPh, R 2 =Ph, R 3 =Me, R4 =H
39. m=l, n=2, R 1 =4-FPh, R 2 =Ph, R 3 =Me, R4 =H
40. m=l, n=2, R 1 =4-FPh, R 2 =4-MeOPh, R 3 =Me, R4 =H
41. m=l, n=l, R 1 =4-NO 2 Ph, R 2 =Ph, R 3 =Me, R4 =H
42. m=l, n=2, R 1 =4-NO 2 Ph, R 2 =Ph, R 3 =Me, R4 =H
43. m=l, n=2, R 1 =4-NO 2 Ph, R 2 =4-MeOPh, R 3 =Me, R4 =H
44. m=l, n=l, R 1 =4-NH 2 Ph, R 2 =Ph, R 3 =Me, R4 =H
45. m=l, n=2, R 1 =4-NH 2 Ph, R 2 =Ph, R 3 =Me, R4 =H
46. m=l, n=2, R 1 =3,4-diMeOPh, R 2 =Ph, R 3 =Me, R4 =H
47. m=l, n=3, R 1 =3,4-diMeOPh, R 2 =Ph, R 3 =Me, R4 =H
48. m=2, n=l, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
49. m=2, n=l, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
50. m=2, n=2, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =H
51. m=2, n=2, R 1 =Ph, R 2 =Ph, R 3 =Me, R4 =CH 3
52. m=2, n=2, R 1 =Ph, R 2 =4-MeOPh, R 3 =Me, R4 =H
53. m=2, n=2, R 1 =4-MeOPh, R 2 =4-MeOPh, R 3 =Me, R4 =H.
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The term "aryl" refers to aromatic groups having 6 to 24
carbon atoms, and "substituted aryl" refers to aryl groups
further bearing one or more substituents.
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The term "alkyl" refers to straight or branched chain alkyl
radicals having 1 to 19 carbon atoms, and "substituted alkyl"
refers to alkyl radicals further bearing one or more substituents.
The term "lower alkyl" refers to straight or branched
chain alkyl radicals having in the range of 1 to 4 carbon
atoms.
The term "cycloalkyl" refers to cyclic ring-containing
moieties containing 3 to 8 carbon atoms, and "substituted
cycloalkyl" refers to cycloalkyl moieties further bearing one
or more substituents.
The term "alkenyl" refers to straight or branched chain
hydrocarbyl groups having at least one carbon-carbon
double bond and having 2 to 19 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or
more substituents.
The term "heterocyclic" refers to cyclic moieties containing one or more heteroatoms as part of the ring structure and
having 3 to 24 carbon atoms, and "substituted heterocyclic"
refers to heterocyclic moieties further bearing one or more
substituents.
Pharmaceutically acceptable salts include c1-, Br-, 1-,
No 2 -, HSO4 -, SO4 -, HPO4 -, Po/-, ethanesulfonate, trifluromethane sulfate, p-toluenesulfonate, benzenesulfonate,
salicylate, proprionate, ascorbate, aspartate, fumarate,
galactarate, maleate, citrate, glutamate, glycolate, lactate,
malate, maleate, tartrate, oxalate, succinate, or similar acid
addition salts. The above salt forms may be in some cases
hydrates or solvates with alcohols and other solvents.
Pharmaceutical Compositions
Also disclosed herein are pharmaceutical compositions
comprising a compound of formula (I) and pharmaceutically
acceptable excipients. For example, the pharmaceutical
composition may include a pharmaceutically acceptable
additive, such as a stabilizer, buffer, salt, preservative, filler,
flavor enhancer and the like, as known to those skilled in the
art. Representative buffers include phosphates, carbonates,
and citrates. Exemplary preservatives include EDTA,
EGTA, BHA, and BHT.
The pharmaceutical composition disclosed herein may be
administered by inhalation (i.e., intranasally as an aerosol or
nasal formulation); topically (i.e., in the form of an ointment, cream or lotion); orally (i.e., in solid or liquid form
(tablet, capsule, gel cap, time release capsule, powder,
solution, or suspension in aqueous or non-aqueous liquid);
intravenously as an infusion or injection (i.e., as a solution,
suspension or emulsion in a pharmaceutically acceptable
carrier); or subcutaneously as an infusion or injection (i.e.,
as a solution, suspension or emulsion in a pharmaceutically
acceptable carrier) or as a depot formulation; transdermally
(e.g., via a transdermal patch), or rectally (e.g., as a suppository).
There is no limitation in the route of administration or
dosage form, and the composition may be administered in
accordance with specific form of the preparation, age, sex
and the other conditions of a patient, severity of disease, etc.
For example, in the case of tablet, pill, solution, suspension,
emulsion, granule and capsule, the composition is orally
administered. In the case of injection, the composition is
intravenously administered alone or in a mixture with conventional replacement fluid such as glucose and amino
acids, and if necessary, and the preparation alone may be
also administered intramuscularly, intracutaneously, subcutaneously or interperitoneally.

The compounds disclosed herein can be administered
alone, combined with a pharmaceutically acceptable excipient, or co-administered with a second drug. Co-administration may provide a similar or synergistic effect. A compound
of formula (I) or a pharmaceutically acceptable salt thereof
can be administered subcutaneously, intramuscularly, intravenously, transdermally, orally, intranasally, intrapulmonary,
or rectally.
The dose of the pharmaceutical composition of the present invention is appropriately selected in accordance with
dosage regimen, age, sex and the other conditions of a
patient. The amount to be administered depends to some
extent on the lipophilicity of the specific compound selected,
since it is expected that this property of the compound will
cause it to partition into fat deposits of the subject. The
precise amount to be administered can be determined by the
skilled practitioner in view of desired dosages, side effects
and medical history of the patient and the like.
The pharmaceutical composition may comprise a compound of formula (I), or an enantiomer or racemate thereof,
or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive or a pharmaceutically acceptable excipient.
Treatment of Drug Abuse
VMAT2 is considered as a valid target for the development of treatments for the abuse of drugs, including, for
example, methamphetamine (METH), amphetamine,
cocaine, methylphenidate, and opiate abuse. For example,
METH decreases vesicular DA sequestration by inhibiting
vesicular uptake through VMAT2 (IC 50 =14.9 µM) and by
diffusing across the vesicular membranes to decrease the pH
gradient, resulting in the loss of free energy needed for
monoamine transport.
Lobelane competitively inhibits [3 H]DA uptake into rat
brain vesicles via interaction with VMAT2 (K,=45 nM),
decreases METH-evoked DA overflow from rat striatal
slices, and decreases METH self-administration, but does
not act as a psychostimulant, suggesting that it has potential
as a novel treatment for METH abuse. Nor-Lobelane (K 1 =44
nM) is equipotent with lobelane at VMAT2 in inhibiting
3
[ H]DA uptake.
METH can be considered as a structural fragment of
lobelane/nor-lobelane, and introducing bulky substituents
onto the N-atom of METH afforded compounds with
increased inhibitory potency at VMAT2, reduced the psychostimulant effects of METH, diminishing its abuse potential. Importantly, these new analogs did not increase locomotor activity in rats, indicating they do not act as
psychostimulants. Lee, N.-R. et al., Drug and Alcohol
Dependence, "Enantiomers of (±)GZ-888 potently and
selectively inhibit vesicular monoamine transporter-2 function and methamphetamine-stimulated locomotor activity,"
(2016).
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Treatment of a Disease or Pathology of the Central Nervous
System or an Eating Disorder
Modulation of VMAT2 has potential as a therapeutic for
central nervous system diseases or pathologies. Thus,
VMAT2 is a target for the development of treatments for a
disease or pathology of the central nervous system, including, for example, cognitive disorders, brain trauma, memory
loss, psychosis, sleep disorders, obsessive compulsive disorders, panic disorders, myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntington's disease, attention deficit hyperactivity
disorder, hyperkinetic syndrome, chronic nervous exhaustion, narcolepsy, pain, motion sickness, and/or depression.
VMAT2 is also a target for the development of treatments
for eating disorders, including, for example, obesity. Compulsive eating is linked to addiction-like neuroadaptive
responses in brain reward circuits. Johnson, P. M. et al.,
"Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats," Nature Neuroscience, 2010, 13, 635-641. Modulation of VMAT2 may
lead to reduced reward responses, diminishing overeating.
A more preferred embodiment of the invention is a
compound of formula (I), wherein the compound is 3-(4methoxypheny1)-N-( l -phenylpropan-2-y l)propan-1-amine
or an enantiomer; racemate; or pharmaceutically acceptable
salt thereof.
An even more preferred embodiment of the invention is a
compound of formula (I), wherein the compound is (S)-3(4-methoxypheny I)-N-(1-pheny lpropan-2-y l)propan-1amine hydrochloride.
A more preferred embodiment of the invention is a
pharmaceutical composition comprising 3-(4-methoxyphenyl)-N-(l-phenylpropan-2-yl)propan-1-amine
or
an
enantiomer; racemate; or pharmaceutically acceptable salt
thereof and a pharmaceutically acceptable additive or a
pharmaceutically acceptable excipient. An even more preferred embodiment of the invention is a pharmaceutical
composition comprising (S)-3-(4-methoxyphenyl)-N-(lphenylpropan-2-yl)propan-l-amine hydrochloride and a
pharmaceutically acceptable additive or a pharmaceutically
acceptable excipient.
Another preferred embodiment of the invention is a
method of treating a disease or pathology of the central
nervous system or an eating disorder in an individual in need
thereof, wherein the method comprises the step of administering to the individual a compound of formula (I) or a
pharmaceutically acceptable salt thereof.
The compounds of the present invention may be used in
a method of treating a disease or pathology of the central
nervous system, wherein the disease may be cognitive
disorders, brain trauma, memory loss, psychosis, sleep disorders, obsessive compulsive disorders, panic disorders,
myasthenia gravis, Parkinson's disease, Alzheimer's disease, schizophrenia, Tourette's syndrome, Huntington's disease, attention deficit hyperactivity disorder, hyperkinetic
syndrome, chronic nervous exhaustion, narcolepsy, pain,
motion sickness, and/or depression.
The compounds of the present invention may also be used
in a method of treating an eating disorder. The eating
disorder may be obesity.
The compounds of the present invention may be used in
a method of treating substance use disorder, drug dependence/abuse or withdrawal from drug dependence/abuse in
an individual in need thereof. Substance use disorder and
drug dependence/abuse includes dependence/abuse of psychostimulants or drugs that release dopamine. For example,

the drug which the individual is using and/or dependent
upon may be amphetamine, methamphetamine, and other
drugs that release dopamine.
5
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EXAMPLES
A series of VMAT2 inhibitors were synthesized and
evaluated for their activity at VMAT2, dopamine transporters (DAT), and serotonin transporters (SERT) using rat
striatum, hERG channels expressed by HEK-293 cells, and
for their effect on METH-stimulated locomotor activity in
rats. Compounds of the invention exhibited affinity at
VMAT2 as well as selectivity at VMAT2 over hERG, DAT,
and SERT. Further, a significant reduction of METH-stimulated locomotor activity was observed after administration
of the compounds.
Example 1
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Synthesis of compound 10. (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-l-amine
To a solution of phenyllithium (50 mL, 1.8 Min dibutyl
ether) in THF (50 mL) was added (R)-propylene oxide (5 g)
dropwise at - 78° C. The resulting mixture was stirred at the
same temperature for 1 hr before warmed to room temperature. After stirred at room temperature overnight, the reaction was quenched by adding saturated NH4 Cl aqueous
solution. The aqueous phase was extracted with ethyl acetate
(3x50 mL) and the combined organic layers were washed
with brine (100 mL), dried over anhydrous Na2 SO4 , filtered
and concentrated under reduced pressure. The crude product
was chromatographed on silica (hexanes/ethyl acetate 10:1
to 3:1) to afford (R)-1-phenylpropan-2-ol (10.4 g) as a
colorless oil.
To a solution of (R)-1-phenylpropan-2-ol (4.16 g, 30.50
mmol) and triethylamine (7.72 g, 10.64 mL, 76.27 mmol) in
dichloromethane (100 mL) was added methanesulfonyl
chloride (4.54 gm, 3.07 mL, 39.65 mmol) dropwise at 0° C.
The resulting mixture was stirred at 0° C. for 15 min.
Dichloromethane (100 mL) was added to the mixture and
then washed with water (2x150 mL). The organic layer was
dried over anhydrous Na 2 SO4 , filtered and concentrated
under reduced pressure. The resulting light yellow oil was
mixed with sodium azide (5.95 g, 91.5 mmol) in DIME (40
mL) and heated at 55° C. for 3 hrs. The reaction mixture was
diluted with diethyl ether (150 mL) and washed with water
(2x100 mL) and brine (100 mL). The organic layer was
dried over anhydrous Na 2 SO4 , filtered and concentrated
under reduced pressure. The crude product was chromatographed on silica (hexanes/ethyl acetate 50:1 to 20:1) to
afford (S)-(2-azidopropyl)benzene (4.38 g) as a colorless oil.
To a solution of (S)-(2-azidopropyl)benzene (4.0 g, 24.81
mmol) in THF (90 mL) and water (10 mL) was added
triphenylphosphine (9.11 g, 34.74 mmol) at room temperature. The resulting mixture was stirred for 18 hrs and water
(50 mL) was added. The resulting mixture was treated with
HCI (1.0 M) to pH-1 and the aqueous phase was extracted
with diethyl ether (3x100 mL) and dichloromethane (2x100
mL). NaOH (15%) was added dropwise to the aqueous
phase to adjust the pH to about 11 and extracted with
dichloromethane (5x60 mL). The combined organic layers
were dried over anhydrous Na 2 SO4 , filtered and concentrated under reduced pressure to afford (S)-l-phenylpropan2-amine as a colorless oil. The crude amino product (3.03 g,
22.41 mmol) was mixed with 3-(4-methoxyphenyl)propanoic acid (4.44 g, 24.65 mmol), and HOBt (3.63 g, 26.89
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mmol) in dichloromethane (60 mL) at room temperature.
Triethylamine (5.67 g, 56.03 mmol) was added followed by
EDCI (5.15 g, 26.89 mmol). The resulting mixture was
stirred overnight. The reaction mixture was diluted with
dichloromethane (100 mL) and washed with water (3x50
mL), and brine (50 mL). The organic layer was dried over
anhydrous Na2 SO4 , filtered and concentrated under reduced
pressure. The crude product was chromatographed on silica
(dichloromethane/ethyl acetate 10: 1) to afford (S)-3-(4methoxypheny1)-N-( l -phenylpropan-2-y l)propanamide
(6.18 g) as a white solid. (S)-3-(4-Methoxyphenyl)-N-(1phenylpropan-2-yl)propanamide (5.0 g, 16.81 mmol) in
THF was cooled to 0° C. LAH (60 mL, 1.0 Min THF) was
added dropwise and the resulted reaction mixture was heated
at reflux for 6 hrs. After cooled to 0° C., water (2.28 mL) was
carefully added, followed by NaOH (15%, 2.28 mL) and
water (6.84 mL). The resulted mixture was warmed to room
temperature and stirred for 2 hrs. Filtered over celite and
washed with ethyl acetate. The filtrate was concentrated
under reduced pressure and the crude product was chromatographed on silica (dichloromethane/methanol 30: 1 to
10:1) to afford compound 10 (4.3 g) as a white solid.

Example 3

Example 2
[
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[

H]Dopamine ([3H]DA) Uptake Assay, Vesicular
Preparation
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H]Dihydrotetrabenazine ([ 3 H]DTBZ) Binding
Assay, Vesicular Preparation

Synaptic vesicles were prepared from rat brain using a
modification of a previously described procedure (Teng et
al., 1998). Briefly, fresh whole brain (excluding cerebellum)
was homogenized using a Teflon pestle (clearance 0.003
inches) with 7 vertical strokes at 800 rpm in 20 vol of
ice-cold 0.32 M sucrose and centrifuged at 1000 g for 12 min
at 4° C. The resulting supernatant (S 1 ) was then centrifuged
at 22,000 g for 10 min at 4° C. The synaptosomal pellets (P 2 )
were homogenized in 18 mL of ice-cold Milli-Q water and
exposed for 5 min for lysing synaptosomes. Osmolarity was
restored by addition of 2 mL of 25 mM HEPES with 100
mM dipotassium tartrate (pH 7 .5). Samples were centrifuged
at 20,000 g for 20 min at 4° C. to remove lysed synaptosomal membranes. MgSO4 (1 mM) was added to the supernatant (S 3 ), and was centrifuged at 100,000 g for 45 min at
4 ° C. The final vesicular pellets (P4 ) were resuspended in
ice-cold assay buffer (see below) providing-15 µg protein/
100 µL, determined by the method of Bradford (1976) using
bovine serum albumin as a the standard. Aliquot parts (100
µL) of suspension of vesicle membrane protein were incubated in assay buffer (25 mM HEPES, 100 mM dipotassium
tartrate, 5 mM MgSO4 , 0.1 mM EDTA and 0.05 mM EGTA,
pH 7.5, at 25° C.) in the presence of3 nM [3 H]DTBZ and
at least 7 concentrations (1 nM-1 mM) of compound for 1 hr
at room temperature. Nonspecific binding was determined in
the presence of 20 µM tetrabenazine, a standard compound.
Assays were performed in duplicate using a 96-well plate
format. Reactions were terminated by filtration of samples
on a Unifilter-96 GF/B filter plates (presoaked in 0.5%
polyethylenimine), using a FilterMate harvester (Packard
BioScience Co., Meriden, Conn.). After washing 5 times
with 350 µL of the ice-cold wash buffer (25 mM HEPES,
100 mM dipotassium tartrate, 5 mM MgSO4 and 10 mM
NaCl, pH 7.5), filter plates were dried, sealed and each well
filled with 40 µL Packard's MicroScint 20 cocktail. Bound
3
[ H]DTBZ was measured using a Packard TopCount NXT
scintillation counter with a Packard Windows NT based
operating system.

3

30

35

Inhibition of [3 H]DA uptake was conducted using isolated
synaptic vesicle preparations (Teng et al., 1997). Briefly, rat
striata were homogenized with 10 up-and-down strokes of a
Teflon pestle homogenizer (clearance-0.003") in 14 ml of
0.32 M sucrose solution. Homogenates were centrifuged
(2,000 g for 10 min at 4 ° C. ), and then the supernatants were
centrifuged (10,000 g for 30 min at 4° C.). Pellets were
resuspended in 2 ml of 0.32 M sucrose solution and subjected to osmotic shock by adding 7 ml of ice-cold MilliQ
water to the preparation. After 1 min, osmolarity was
restored by adding 900 µI of0.25 M HEPES buffer and 900
µI of 1.0 M potassium tartrate solution. Samples were
centrifuged (20,000 g for 20 min at 4° C.), and the supernatants were centrifuged (55,000 g for 1 hr at 4° C.),
followed by addition of 100 µI of 10 mM MgSO4 , 100 µI of
0.25 M HEPES and 100 µI of 1.0 M potassium tartrate
solution prior to the final centrifugation (100,000 g for 45
min at 4° C.). Final pellets were resuspended in 2.4 ml of
assay buffer (25 mM HEPES, 100 mM potassium tartrate, 50
µM EGTA, 100 µM EDTA, 1.7 mM ascorbic acid, 2 mM
ATP-Mg 2 +, pH 7.4). Aliquots of the vesicular suspension
(100 µ!) were added to tubes containing assay buffer, various
concentrations of compound (0.1 nM-10 mM) and 0.1 µM
3
[ H]DA in a final volume of 500 µ!, and incubated at 37° C.
for 8 min. Nonspecific uptake was determined in the presence of the standard compound, Ro4-1284 (10 µM). Reactions were terminated by filtration, and radioactivity retained
by the filters was determined by liquid scintillation spectrometry (Tri-Carb 2100TR liquid scintillation analyzer;
PerkinElmer Life and Analytical Sciences, Boston, Mass.).
Example 4
[
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3

H]Dofetilide Binding Assay, HEK-293 Cell
Membrane Preparation

3
[ H]Dofetilide binding assays were conducted using commercially available HEK-293 cell membranes which stably
express the hERG charmel. Membranes were suspended in
assay buffer (50 mM Tris, 10 mM KC!, 1 mM MgCl 2 , pH
7.4) prior to the experiment. Assays were performed in
duplicate in a total volume of 250 µL. Aliquots of the
HEK-293 cell membrane suspension which contained 5 µg
membrane protein were added to tubes containing assay
buffer, 5 nM [3 H]dofetilide and a range of concentrations of
analog (10 nM-100 µM). Nonspecific binding was determined in the presence of amitriptyline (1 mM). Samples
were incubated for 1 hr. at 24° C., followed by rapid
filtration. Radioactivity retained by the filters was determined by liquid scintillation spectrometry as described
above for the [3 H]DA uptake assay. The affinity for the
3
[ H]dofetilide binding site on the hERG channel expressed
in the HEK-293 cellular membrane was determined from the
analog concentration response curves.

60

Example 5
[

3

H]DA and [3 H]5-HT Uptake Assay, Synaptosomal
Preparation

65

H]DA and [3 H]5-HT uptake into striatal synaptosomes
was determined to evaluate compound inhibition of the
[

3
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dopamine transporter (DAT) and the serotonin transporter
(SERT), respectively. Striata from individual rats were
homogenized in ice-cold sucrose solution containing 5 mM
NaHCO 3 (pH 7.4), with 16 up-and-down strokes ofa Teflon
pestle homogenizer (clearance,.,0.003"). Homogenates were
centrifuged at 2000 g for 10 min at 4 ° C., and resulting
supematants were centrifuged at 20,000 g for 17 min at 4°
C. Pellets were resuspended in 2.4 mL (for DAT assays) or
1.5 mL (for SERT assays) of assay buffer (125 mM NaCl, 5
mM KC!, 1.5 mM MgSO4 , 1.25 mM CaCl 2 , 1.5 mM
KH 2 PO4 , 10 mM alpha-D-glucose, 25 mM HEPES, 0.1 mM
EDTA, 0.1 mM pargyline, 0.1 mM ascorbic acid, saturated
with 95% 0i5% CO 2 , pH 7.4). Assays were performed in
duplicate in a total volume of 500 µL (for DAT assays) or
250 µL (for SERT assays). Aliquots of the synaptosomal
suspension (25 µL for DAT, 50 µL for SERT) were added to
tubes containing assay buffer and various concentrations of
analog (1 nM-100 µM), and incubated at 34° C. for 5 min.

Nonspecific uptake was determined in the presence of
nomifensine (10 µM) for DAT assays or fluoxetine (10 µM)
for SERT assays. GBR-12935 (100 nM) was included in the
assay buffer for the SERT assay to maximally inhibit [3 H]
5-HT uptake through DAT and isolate uptake to SERT.
Samples were placed on ice, and 50 µL of 0.1 µM [3 H]DA
(for DAT assays) or 25 µL of 0.1 µM [3 H]5-HT (for SERT
assays) was added to each tube, and incubated for 10 min at
34° C. Reactions were terminated by addition of 3 mL of
ice-cold assay buffer and subsequent filtration and radioactivity retained by the filters was determined by liquid
scintillation spectrometry (Tri-Carb 2100TR liquid scintillation analyzer; PerkinElmer Life and Analytical Sciences,
Boston, Mass.).
Exemplary compounds 1-53 were tested in [3 H]dihydrotetrabenazine ([ 3 H]DTBZ) binding assay according to
Example 2 and the [3 H]dopamine ([ 3 H]DA) uptake assay
according to Example 3. The results of these assays are set
forth in Table 1.
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TABLE 1
3
H]DTBZ binding [3 H]DA Uptake (Ki)
(Ki) VMAT2 (µM)
VMAT2 (µM)

[

Compound

Structure

7.70 ± 1.25

0.063 ± 0.005

7.53 ± 2.16

0.51 ± 0.10

1.23 ± 0.13

0.033 ± 0.007

~~
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0.007 ± 0.002
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TABLE I-continued

3
H]DTBZ binding [3 H]DA Uptake (Ki)
(Ki) VMAT2 (µM)
VMAT2 (µM)

[

Compound

Structure
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TABLE I-continued
3
H]DTBZ binding [3 H]DA Uptake (Ki)
(Ki) VMAT2 (µM)
VMAT2 (µM)

[

Compound

Structure

~~

17

0.63

0.014 ± 0.001

0.91 ± 0.59

0.009 ± 0.002

4.1 ± 0.3

0.059 ± 0.007

2.0 ± 0.1

0.0013 ± 0.009

1.5 ± 0.2

0.12 ± 0.01

2.0 ± 0.1

0.12 ± 0.001

3.4 ± 0.6

0.092 ± 0.017

3.77 ± 0.99

0.074 ± 0.002
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1.27 ± 0.09
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TABLE I-continued
3
H]DTBZ binding [3 H]DA Uptake (Ki)
(Ki) VMAT2 (µM)
VMAT2 (µM)

[

Compound

Structure
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TABLE I-continued
3
H]DTBZ binding [3 H]DA Uptake (Ki)
(Ki) VMAT2 (µM)
VMAT2 (µM)

[

Compound

Structure
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TABLE I-continued
[

Compound

Structure
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3

H]DTBZ binding [3 H]DA Uptake (Ki)

(Ki) VMAT2 (µM)

VMAT2 (µM)

2.8 ± 0.7

0.036 ± 0.003

3.8 ± 0.1
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0.029 ± 0.011
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29.8 ± 11.2

0.084 ± 0.004

4.81 ± 1.13

0.050 ± 0.012

17.2 ± 6.33

0.36 ± 0.034

3.2 ± 0.1

0.026 ± 0.002

1.5 ± 0.7

0.024 ± 0.006

me,

~
/OX)!~
'-.. I
#

HCl

0
47

/OX)IN~
I ,-::::;
H

'---o I ,-::::;
48

HCI

"¾

N~
I
H

#

#

HCl

49

"¾

CH3

I

#

N~
I
#

HCl

50

"¾
#

ij~
HCl

51

"¾
#

I~
~

N

HCl
52

~

~o,
HCl

53

/0

~

~o,
HCl

US 10,668,030 B2
23

24

As illustrated by Table 1, compounds of the invention
exhibited high affinity at VMAT2 as well as selectivity at
VMAT2 over hERG, DAT, and SERT. For example, Compound 9 exhibited a K 1 value of 8.71±3.65 at VMAT2, and
Compound 10 exhibited a K 1 value of 25.5±3.57 nM at
VMAT2. Further, both Compound 9 and Compound 10
exhibited a >30-fold selectivity at VMAT2 over hERG,
DAT, and SERT.

The invention claimed is:
1. A method of treating a substance use disorder of
methamphetamine, drug dependence/abuse of methamphetamine, or withdrawal from drug dependence/abuse of methamphetamine in an individual in need thereof comprising
administering a compound of formula (I), where the compound of formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan-2-yl)propan-1-amine; (R)-3-(4-methoxyphenyl)N-(l-phenylpropan-2-yl)propan-l-amine;
or
pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the compound of
formula (I) is (S)-3-(4-methoxyphenyl)-N-(1-phenylpropan2-yl)propan-1-amine hydrochloride.
3. The method of claim 1, wherein the (S)-3-( 4-methoxyphenyl)-N-(l-phenylpropan-2-yl)propan-1-amine; (R)-3-(4methoxyphenyl)-N-(l-phenylpropan-2-yl)propan-1-amine;
or pharmaceutically acceptable salt thereof is present in a
pharmaceutical composition further comprising a pharmaceutically acceptable excipient.
4. The method of claim 3, wherein the pharmaceutical
con_iposition is administered to the individual by inhalation;
topically; orally; intravenously as an infusion or injection; or
subcutaneously as an infusion, injection, or depot formulation; transdermally; or rectally.

The compounds of the invention were also evaluated for
their effect on METH-stimulated locomotor activity was
evaluated in rats. The compounds were observed to exhibit
a significant reduction of METH-stimulated locomotor
activity after administration. For example, a significant
reduction of METH-stimulated locomotor activity was
observed after administration of Compound 9 (3 mg/kg, s.c.)
and Compound 10 (17 mg/kg, s.c.).
The foregoing description and examples have been set
forth merely to illustrate the invention and are not meant to
be limiting. Since modifications of the described embodiments incorporating the spirit and the substance of the
invention may occur to persons skilled in the art, the
invention should be construed broadly to include all variations within the scope of the claims and equivalents thereof.
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